vs

Side-by-side financial comparison of Arcutis Biotherapeutics, Inc. (ARQT) and JBG SMITH Properties (JBGS). Click either name above to swap in a different company.

Arcutis Biotherapeutics, Inc. is the larger business by last-quarter revenue ($129.5M vs $127.6M, roughly 1.0× JBG SMITH Properties). Arcutis Biotherapeutics, Inc. runs the higher net margin — 13.4% vs -35.7%, a 49.1% gap on every dollar of revenue. On growth, Arcutis Biotherapeutics, Inc. posted the faster year-over-year revenue change (81.5% vs -2.5%). Over the past eight quarters, Arcutis Biotherapeutics, Inc.'s revenue compounded faster (61.6% CAGR vs -6.3%).

Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.

JBG SMITH Properties is a publicly traded real estate investment trust based in Bethesda, Maryland.

ARQT vs JBGS — Head-to-Head

Bigger by revenue
ARQT
ARQT
1.0× larger
ARQT
$129.5M
$127.6M
JBGS
Growing faster (revenue YoY)
ARQT
ARQT
+83.9% gap
ARQT
81.5%
-2.5%
JBGS
Higher net margin
ARQT
ARQT
49.1% more per $
ARQT
13.4%
-35.7%
JBGS
Faster 2-yr revenue CAGR
ARQT
ARQT
Annualised
ARQT
61.6%
-6.3%
JBGS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARQT
ARQT
JBGS
JBGS
Revenue
$129.5M
$127.6M
Net Profit
$17.4M
$-45.5M
Gross Margin
91.0%
Operating Margin
14.2%
-47.5%
Net Margin
13.4%
-35.7%
Revenue YoY
81.5%
-2.5%
Net Profit YoY
261.2%
24.0%
EPS (diluted)
$0.14
$-0.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARQT
ARQT
JBGS
JBGS
Q4 25
$129.5M
$127.6M
Q3 25
$99.2M
$123.9M
Q2 25
$81.5M
$126.5M
Q1 25
$65.8M
$120.7M
Q4 24
$71.4M
$130.8M
Q3 24
$44.8M
$136.0M
Q2 24
$30.9M
$135.3M
Q1 24
$49.6M
$145.2M
Net Profit
ARQT
ARQT
JBGS
JBGS
Q4 25
$17.4M
$-45.5M
Q3 25
$7.4M
$-28.6M
Q2 25
$-15.9M
$-19.2M
Q1 25
$-25.1M
$-45.7M
Q4 24
$-10.8M
$-59.9M
Q3 24
$-41.5M
$-27.0M
Q2 24
$-52.3M
$-24.4M
Q1 24
$-35.4M
$-32.3M
Gross Margin
ARQT
ARQT
JBGS
JBGS
Q4 25
91.0%
Q3 25
91.2%
Q2 25
90.8%
Q1 25
86.6%
Q4 24
90.3%
Q3 24
87.7%
Q2 24
88.8%
Q1 24
93.4%
Operating Margin
ARQT
ARQT
JBGS
JBGS
Q4 25
14.2%
-47.5%
Q3 25
8.6%
-27.5%
Q2 25
-17.9%
-18.4%
Q1 25
-37.3%
-44.7%
Q4 24
-10.7%
-53.6%
Q3 24
-87.3%
-22.4%
Q2 24
-162.3%
-24.3%
Q1 24
-63.8%
-30.1%
Net Margin
ARQT
ARQT
JBGS
JBGS
Q4 25
13.4%
-35.7%
Q3 25
7.5%
-23.1%
Q2 25
-19.5%
-15.2%
Q1 25
-38.1%
-37.9%
Q4 24
-15.1%
-45.8%
Q3 24
-92.8%
-19.8%
Q2 24
-169.6%
-18.0%
Q1 24
-71.4%
-22.2%
EPS (diluted)
ARQT
ARQT
JBGS
JBGS
Q4 25
$0.14
$-0.76
Q3 25
$0.06
$-0.48
Q2 25
$-0.13
$-0.29
Q1 25
$-0.20
$-0.56
Q4 24
$-0.09
$-0.70
Q3 24
$-0.33
$-0.32
Q2 24
$-0.42
$-0.27
Q1 24
$-0.32
$-0.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARQT
ARQT
JBGS
JBGS
Cash + ST InvestmentsLiquidity on hand
$42.9M
$75.3M
Total DebtLower is stronger
$109.0M
Stockholders' EquityBook value
$189.5M
$1.2B
Total Assets
$433.0M
$4.4B
Debt / EquityLower = less leverage
0.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARQT
ARQT
JBGS
JBGS
Q4 25
$42.9M
$75.3M
Q3 25
$47.1M
$64.4M
Q2 25
$72.7M
$61.4M
Q1 25
$53.1M
$81.3M
Q4 24
$71.3M
$145.8M
Q3 24
$134.9M
$137.0M
Q2 24
$84.3M
$163.5M
Q1 24
$190.1M
$220.5M
Total Debt
ARQT
ARQT
JBGS
JBGS
Q4 25
$109.0M
Q3 25
$108.5M
Q2 25
$108.0M
Q1 25
$107.6M
Q4 24
$107.2M
Q3 24
$204.6M
Q2 24
$203.8M
Q1 24
$202.8M
Stockholders' Equity
ARQT
ARQT
JBGS
JBGS
Q4 25
$189.5M
$1.2B
Q3 25
$158.1M
$1.2B
Q2 25
$139.0M
$1.3B
Q1 25
$142.7M
$1.6B
Q4 24
$157.5M
$1.8B
Q3 24
$156.6M
$1.9B
Q2 24
$186.4M
$2.0B
Q1 24
$224.9M
$2.1B
Total Assets
ARQT
ARQT
JBGS
JBGS
Q4 25
$433.0M
$4.4B
Q3 25
$371.0M
$4.4B
Q2 25
$352.4M
$4.5B
Q1 25
$344.1M
$4.7B
Q4 24
$348.9M
$5.0B
Q3 24
$437.4M
$5.2B
Q2 24
$444.8M
$5.3B
Q1 24
$478.5M
$5.4B
Debt / Equity
ARQT
ARQT
JBGS
JBGS
Q4 25
0.58×
Q3 25
0.69×
Q2 25
0.78×
Q1 25
0.75×
Q4 24
0.68×
Q3 24
1.31×
Q2 24
1.09×
Q1 24
0.90×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARQT
ARQT
JBGS
JBGS
Operating Cash FlowLast quarter
$26.2M
$73.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.51×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARQT
ARQT
JBGS
JBGS
Q4 25
$26.2M
$73.3M
Q3 25
$-1.8M
$8.9M
Q2 25
$324.0K
$18.8M
Q1 25
$-30.4M
$12.9M
Q4 24
$-748.0K
$129.4M
Q3 24
$-34.7M
$26.4M
Q2 24
$-45.1M
$23.8M
Q1 24
$-31.6M
$37.0M
Free Cash Flow
ARQT
ARQT
JBGS
JBGS
Q4 25
Q3 25
Q2 25
$246.0K
Q1 25
$-31.0M
Q4 24
Q3 24
$-34.8M
Q2 24
Q1 24
FCF Margin
ARQT
ARQT
JBGS
JBGS
Q4 25
Q3 25
Q2 25
0.3%
Q1 25
-47.1%
Q4 24
Q3 24
-77.8%
Q2 24
Q1 24
Capex Intensity
ARQT
ARQT
JBGS
JBGS
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.1%
Q1 25
0.9%
Q4 24
0.0%
Q3 24
0.3%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
ARQT
ARQT
JBGS
JBGS
Q4 25
1.51×
Q3 25
-0.24×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons